Scholars Central

Research articlePublished 25 Apr 2022

Bioequivalence study of a new fixed-dose combination tablet containing irbesartan and hydrochlorothiazide in healthy volunteers

Authors: Katya Uzunova, Andrey Petrov, Emil Gatchev, Velichka Pavlova, Elena Filipova, Cintia Jimenez, Krassimir Kalinov, Toni Vekov

Health Science Journal

Volume 16 · Issue 3 · Pages 1–7

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background and objective: The combination antihypertensive therapy has shown greater blood pressure lowering potential as well as better adherence to the treatment. Therefore, a new generic fixed-dose combination containing irbesartan and hydrochlorothiazide was developed and rate and extend of absorption were compared with reference formulation to prove its bioequivalence in healthy volunteers. Methods: A single-centre, open-label, randomized, two-period, crossover, single dose study under fasting conditions, including at least 7-days washout period, was performed in 30 healthy male and female volunteers. Twenty blood samples were collected in each study period: prior to dosing (0:00) and up to 72:00 hours after dosing and plasma concentrations of irbesartan and hydrochlorothiazide were analysed using preliminary validated methods. Results: The 90% CIs for the geometric mean ratios of test and reference of Cmax and AUC0–t were 89.22% to 98.80% and 100.58% to 115.11%, respectively, for irbesartan and 91.80% to 122.96% and 94.88% to 117.56%, respectively. Thus, the corresponding ratios of Cmax and AUC0-t for irbesartan and hydrochlorothiazide met the predetermined criteria for bioequivalence (90% confidence intervals of the geometric mean ratios of test and reference within the 80.00% - 125.00%). Both the test and reference products demonstrated good tolerability profile in this population, and no serious AEs were observed. Conclusions: Therefore, the test product (Irbesartan/hydrochlorothiazide 300/25 mg film-coated tablets, manufactured by Tchaikapharma High Quality Medicines Inc., Bulgaria) and the reference product (CoAprovel 300/25 mg film-coated tablets, manufactured by Sanofi Clir SNC, France) are considered bioequivalent.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Health Science Journal.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalHealth Science Journal
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Katya Uzunova”
  • BylineArticles whose byline prints “Andrey Petrov”
  • BylineArticles whose byline prints “Emil Gatchev”
  • BylineArticles whose byline prints “Velichka Pavlova”
  • BylineArticles whose byline prints “Elena Filipova”
  • BylineArticles whose byline prints “Cintia Jimenez”
  • BylineArticles whose byline prints “Krassimir Kalinov”
  • BylineArticles whose byline prints “Toni Vekov”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels